Startups

CVERGENX, in collaboration with investigators at the Moffitt Cancer Center, has developed a unique molecular diagnostic assay that identifies differences in tumor radiosensitivity, which allows the appropriate selection of patients most likely to benefit from Radiation Therapy.

A specialty pharmaceutical company that is developing new formulations of Farnesyl DiMethyl Chromanol for the treatment and prevention of pancreatic cancer.

We are a start-up company based in Jupiter, Florida and we are focused on the treatment of cancer using novel compound technologies discovered at the Moffitt Cancer Center in Tampa, Florida and exclusively licensed by us from them.

A Moffitt Medical Device start-up developing the Anesthesia Intra-oral Monitoring System (AIMS) technology invented at Moffitt.

M2GEN^® is a health informatics solutions company focused on accelerating the discovery and development of precision medicine. By creating a large, cancer-focused data warehouse linking clinical and molecular data, M2GEN helps biopharmaceutical companies address the challenges in oncology drug development.

A therapeutics company developing Akt inhibitors for treating different malignant tumors including breast, prostate, and ovarian.

We are dedicated towards improving patient outcomes by developing novel approaches for targeting cell adhesion molecules critical for mediating drug resistance and survival of tumor cells.

[link]

OncoBay Clinical is a boutique contract research boutique contract research organization (CRO) specializing in immuno-oncology/cell therapy, offering full- service custom-curated CRO solutions for global pharmaceutical and biotech companies looking to advance their immuno-oncology product or device.

A molecular diagnostics company developing Akt and histone phosphorylation tests for predicting response to therapies.

A therapeutics company developing bifunctional immunoconjugates that are cancer cell binding agents linked to immune system activators. These agents help target the immune system activators to the tumor microenvironment and cancer cells focusing an immune attack on the tumor while avoiding normal, non-cancer cells.

A medical device company developing an improved wide band tourniquet for blood draws.